IL1B and retinal dystrophy, optic nerve edema, splenomegaly, anhidrosis, and migraine headache syndrome: At present, there is no approved drug for ROSAH syndrome, and patients have been typically treated with anti-TNF and IL-1 inhibitors3,15–17.